^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    COH29

    i
    Other names: COH29, City of Hope 29
    Associations

    News

    Trials
    Company:
    City of Hope, Novonco Therap
    Drug class:
    Ribonucleotide reductase inhibitor
    Related drugs:
    Associations

    News

    Trials
    23d
    RRM2 inhibition alters cell cycle through ATM/Rb/E2F1 pathway in atypical teratoid rhabdoid tumor. (PubMed, Neoplasia)
    Our study highlights the role of ATM/Rb/E2F1 pathway in controlling cell cycle arrest and apoptosis in response to RRM2 inhibition-induced DNA damage. This provides insight into the therapeutic benefits of COH29 and suggests targeting this pathway as a potential treatment for ATRT.
    Journal
    |
    HRD (Homologous Recombination Deficiency) • RRM2 (Ribonucleotide Reductase Regulatory Subunit M2) • E2F1 (E2F transcription factor 1)
    |
    COH29
    9ms
    RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024
    Trial completion date
    |
    COH29
    11ms
    Targeting of RRM2 suppresses DNA damage response and activates apoptosis in atypical teratoid rhabdoid tumor. (PubMed, J Exp Clin Cancer Res)
    Collectively, our study uncovers the oncogenic functions of RRM2 in ATRT cell lines, and highlights the therapeutic potential of targeting RRM2 in ATRT. The promising effect of COH29 on ATRT suggests its potential suitability for clinical trials as a novel therapeutic approach for ATRT.
    Journal
    |
    RRM2 (Ribonucleotide Reductase Regulatory Subunit M2)
    |
    COH29
    12ms
    The key cellular senescence related molecule RRM2 regulates prostate cancer progression and resistance to docetaxel treatment. (PubMed, Cell Biosci)
    Our findings suggest that RRM2 regulates docetaxel resistance in prostate cancer by stabilizing ANXA1-mediated activation of the PI3K/AKT pathway. Targeting RRM2 or ANXA1 may offer a promising therapeutic strategy to overcome docetaxel resistance in prostate cancer.
    Journal
    |
    ANXA1 (Annexin A1) • RRM2 (Ribonucleotide Reductase Regulatory Subunit M2)
    |
    AKT1 overexpression • ANXA1 overexpression • ANXA1 expression
    |
    docetaxel • COH29
    over1year
    RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, City of Hope Medical Center | Suspended --> Active, not recruiting | N=19 --> 12 | Trial completion date: Dec 2022 --> Dec 2023
    Enrollment closed • Enrollment change • Trial completion date
    |
    H2AX (H2A.X Variant Histone)
    |
    COH29